Rovner ES - Search Results

1

A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology.

Rovner ES, Carlson KV, Deal AS, Nair KV, Oakkar EE, Park J, Gemmen E, Kristy RM, Gooch KL, Schermer CR. Rovner ES, et al. Contemp Clin Trials. 2018 Jul;70:83-87. doi: 10.1016/j.cct.2018.05.006. Epub 2018 May 16. Contemp Clin Trials. 2018. PMID: 29777865 Free article.

2

Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.

Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z; 037 Study Group. Rovner ES, et al. Urology. 2008 Sep;72(3):488-93. doi: 10.1016/j.urology.2008.05.019. Epub 2008 Jul 17. Urology. 2008. PMID: 18639327 Clinical Trial.

3

Urodynamics in the evaluation of overactive bladder.

Rovner ES, Goudelocke CM. Rovner ES, et al. Curr Urol Rep. 2010 Sep;11(5):343-7. doi: 10.1007/s11934-010-0130-8. Curr Urol Rep. 2010. PMID: 20585906 Review.

4

Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder.

Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Rovner E, et al. Neurourol Urodyn. 2011 Apr;30(4):556-62. doi: 10.1002/nau.21021. Epub 2011 Feb 23. Neurourol Urodyn. 2011. PMID: 21351127 Clinical Trial.

5

Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).

Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Schermer CR. Carlson KV, et al. Among authors: rovner es. Adv Ther. 2019 Aug;36(8):1906-1921. doi: 10.1007/s12325-019-00994-7. Epub 2019 Jun 20. Adv Ther. 2019. PMID: 31222714 Free PMC article.

6

One-year results with selective bladder denervation in women with refractory overactive bladder.

Rovner ES, Versi E, Le Mai T, Dmochowski RR, De Wachter S. Rovner ES, et al. Neurourol Urodyn. 2019 Nov;38(8):2178-2184. doi: 10.1002/nau.24110. Epub 2019 Jul 29. Neurourol Urodyn. 2019. PMID: 31359508

7

Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study.

Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC. Carlson KV, et al. Among authors: rovner es. Low Urin Tract Symptoms. 2021 Oct;13(4):425-434. doi: 10.1111/luts.12382. Epub 2021 May 14. Low Urin Tract Symptoms. 2021. PMID: 33987973 Free PMC article.

8

Does urinary urgency drive urinary frequency in overactive bladder?

Versi E, Rovner ES, Dmochowski RR, Tu LM, De Wachter S. Versi E, et al. Among authors: rovner es. Low Urin Tract Symptoms. 2022 Jul;14(4):242-247. doi: 10.1111/luts.12427. Epub 2022 Feb 28. Low Urin Tract Symptoms. 2022. PMID: 35233968

9

Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder.

Dmochowski RR, Rovner ES, Kennelly MJ, Newman DK, Abedinzadeh L, Snyder D, Thomas E, Haag-Molkenteller C, Rosenberg MT. Dmochowski RR, et al. Among authors: rovner es. BMC Urol. 2023 Apr 24;23(1):64. doi: 10.1186/s12894-023-01240-7. BMC Urol. 2023. PMID: 37095473 Free PMC article. Clinical Trial.

10

The overactive bladder: an overview for primary care health providers.

Wein AJ, Rovner ES. Wein AJ, et al. Among authors: rovner es. Int J Fertil Womens Med. 1999 Mar-Apr;44(2):56-66. Int J Fertil Womens Med. 1999. PMID: 10338262 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

178 results

Search Page

Filters